We're both spitballing Tada....We've already got a licensing deal in China and "the territories", then another ROFR deal for the US market.  Then there's the Royalty Preferred shares and the Zenith connection.  It makes me wonder if the structure is maybe too convoluted....and if that's a barrier to a BP getting involved.  

Let's say a Pfizer wants in, seeing global value of $10 billion for Apabetalone (spitballing again)....Okay, but there's already a deal for China, so either negotiate a side deal with Hepalink or leave China and the territories out of the equation.  And another deal with HL USA to get them to drop their RFR....oh and then there's the royalites.  

Anyway, merry Christmas and happy new year.....